A citation-based method for searching scientific literature

Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
Times Cited: 57



Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
Times Cited: 150




List of shared articles



Times cited

SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
Nabila Ahmed-Sarwar, Angela K Nagel, Samantha Leistman, Kevin Heacock. Ann Pharmacother 2017
8


Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
12

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale. Clin Ther 2016
104

Dapagliflozin for the treatment of type 1 diabetes mellitus.
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Expert Opin Investig Drugs 2017
3


Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
Leyna Leite Santos, Fernando José Camello de Lima, Célio Fernando de Sousa-Rodrigues, Fabiano Timbó Barbosa. Rev Assoc Med Bras (1992) 2017
10

Adjunctive therapy for glucose control in patients with type 1 diabetes.
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise. Diabetes Metab Syndr Obes 2018
10



Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
Laura Van den Mooter, Simon Caerels, Chantal Mathieu. Expert Opin Pharmacother 2018
1

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
156


SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
7

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis.
Gretchen M Ray, Chelsea Rodriguez, Samantha M Schulman, Preeyaporn Sarangarm, Michelle Bardack, Matthew F Bouchonville. Clin Pract Cases Emerg Med 2019
2